Skip to main content

Advertisement

Table 4 Use of vascular disease preventative drugs by geographical region

From: Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study

  All China South Asia East Asia North Africa Middle East Latin America Russia
Patients with macrovascular complications         
RAS blocker, n (%) 13,910 (78.1) 1,303 (55.6) 3,771 (76.3) 1,992 (74.2) 778 (79.5) 3,719 (86.6) 285 (85.1) 2,062 (92.6)
Aspirin, n (%) 13,995 (78.6) 1,644 (70.2) 3,784 (76.6) 1,866 (69.5) 801 (81.8) 3,973 (92.5) 252 (75.2) 1,675 (75.2)
Statins, n (%) 11,958 (67.2) 1,139 (48.6) 3,057 (61.9) 1,846 (68.8) 715 (73.0) 3,710 (86.4) 189 (56.4) 1,302 (58.5)
Patients with microvascular complications         
RAS blocker, n (%) 21,884 (62.6) 2,268 (41.5) 4,792 (58.5) 3,465 (61.7) 1,557 (65.0) 6,907 (70.1) 499 (69.8) 2,396 (87.3)
Aspirin, n (%) 22,207 (63.5) 2,704 (49.5) 4,958 (60.6) 2,698 (48.0) 1,598 (66.7) 7,922 (80.5) 427 (59.7) 1,900 (69.2)
Statins, n (%) 19,709 (56.4) 1,856 (33.9) 4,325 (52.8) 3,133 (55.8) 1,288 (53.7) 7,323 (74.4) 312 (43.6) 1,472 (53.6)
  1. Note: due to the observational nature of this study, not all baseline data were recorded.
  2. RAS = renin-angiotensin system.